Financial Performance - Q3 2025 revenue increased to $60.1 million, a 23.5% year-over-year growth[11] - Net income for Q3 2025 was $0.7 million, compared to a loss of $1.9 million in Q3 2024[22] - Adjusted EBITDA for Q3 2025 was $9.2 million, with an Adjusted EBITDA margin of 15.4%[22] - Operational cash increased by $3.9 million, reaching $39.8 million as of September 30, 2025[24] Business Growth & Development - High Potential (HiPo) accounts contributed approximately 64% of year-over-year revenue growth[11] - HiPo accounts showed a 19% year-over-year increase in average account productivity[11] - The company trained 62 surgeon pairs in Breast procedures YTD, with 281 procedures performed in Q3, a 20% year-over-year increase[11] - The company trained 57 surgeons in OMF/H&N procedures YTD, exceeding the target of 45[11] - Approximately 1.1 million estimated additional covered lives were added in Q3, with approximately 18.1 million new lives YTD[13] Guidance - The company is raising guidance for the full year 2025, projecting revenue growth of at least 19%, or $222.8 million[26]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Axogen, Inc. and its officers or directors [1] Group 1: Company Developments - On August 25, 2025, Axogen announced that the FDA extended the PDUFA goal date for its Biologics License Application for Avance® Nerve Graft by three months to December 5, 2025 [3] - Following this announcement, Axogen's stock price decreased by $1.47 per share, or 9.04%, closing at $14.79 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is representing investors in investigating claims against Axogen for possible securities fraud or other unlawful business practices [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4]